Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.55 |
| ▸ | KDR | P35968 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8213706 | 0.95 | HDAC1 (0.72) | HDAC1HDAC8HDAC6HDAC3HDAC2 | |
| SCHEMBL4737106 | 0.94 | HDAC1 (0.73) | HDAC1HDAC8HDAC6HDAC3HDAC2 | |
| SCHEMBL4737144 | 0.93 | HDAC1 (0.73) | HDAC1HDAC8HDAC6HDAC3HDAC2 | |
| SCHEMBL4787633 | 0.93 | HDAC1 (0.73) | HDAC1HDAC8HDAC6HDAC3HDAC2 | |
| SCHEMBL14067212 | 0.91 | EGFR (0.58) | HDAC1HDAC8HDAC6HDAC3HDAC2 | |
| SCHEMBL14067214 | 0.90 | EGFR (0.59) | HDAC1HDAC8HDAC6HDAC3HDAC2 | |
| SCHEMBL3960004 | 0.87 | HDAC1 (0.60) | HDAC1HDAC8HDAC6HDAC3HDAC2 | |
| SCHEMBL3963494 | 0.86 | HDAC1 (0.60) | HDAC1HDAC8HDAC6HDAC3HDAC2 | |
| SCHEMBL3954468 | 0.86 | HDAC1 (0.60) | HDAC1HDAC8HDAC6HDAC3HDAC2 | |
| SCHEMBL3962758 | 0.86 | HDAC1 (0.58) | HDAC1HDAC8HDAC6HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009036057-A1 | ANTIPROLIFERATIVE AGENTS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | HDAC1 1/4885HDAC8 4/4885HDAC6 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.